Topical imiquimod as neoadjuvant therapy before Mohs micrographic surgery for basal cell carcinoma in the head and neck region: findings from a large retrospective study

2021 ◽  
Author(s):  
C. Queirós ◽  
L. Silva ◽  
A. Miroux Catarino ◽  
J. Labareda ◽  
G. Catorze ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Neoadjuvant Therapy ◽  
Neck Region ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery ◽  
Head And Neck Region ◽  
Large Retrospective Study

Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases

2018 ◽  
Vol 43 (5) ◽  
pp. 1321-1327 ◽  
Author(s):  
Elsa M. Kuiper ◽  
Bente A. van den Berge ◽  
Julia R. Spoo ◽  
Jeroen Kuiper ◽  
Jorrit B. Terra
Keyword(s):  
Retrospective Study ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Recurrence Rate ◽  
Basal Cell ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery

scholarly journals Incomplete excision of basal cell carcinoma (BCC) in the head and neck region: to wait, or not to wait?

2017 ◽  
Vol 34 (6) ◽  
pp. 607-611 ◽  
Author(s):  
Jakub Miszczyk ◽  
Michał Charytonowicz ◽  
Tomasz Dębski ◽  
Bartłomiej Noszczyk
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Basal Cell ◽  
Neck Region ◽  
Head And Neck Region ◽  
Incomplete Excision

Occurrence and recurrence of basal cell carcinoma of the head and neck in negroid and albinoid africans

1987 ◽  
Vol 101 (12) ◽  
pp. 1324-1328 ◽  
Author(s):  
S. A. Ademiluyi ◽  
G. T. A. Ijaduola
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Recurrence Rate ◽  
Basal Cell ◽  
Neck Region ◽  
Head And Neck Region ◽  
Outdoor Workers ◽  
Significant Difference

SummaryA study of sixty patients with basal cell carcinoma of the head and neck region carried out over a six-year period (1979–1985) is hereby presented. Sixteen (26.72 percent) were albinos and 44 (73.28 per cent) negroids. Forty-eight (80 per cent) were outdoor workers. The negroid patients presented between the 3rd and 4th decades while the albinos presented a decade earlier. The commonest site involved in the head and neck was the forehead. The midface showed the highest recurrence rate in both groups, even after adequate excision. The frequency of recurrence in tumours presenting with a size of 2–5 cm. diameter was significantly higher in the albinos than in the negroid (P<0.05), whereas, with tumours of a size larger than 5 cm., there was no statistically significant difference between the albino and the negroid. However, the overall recurrence rate was significantly higher in the albinos (P<0.005). The mortality among the albinos was 25 per cent while there were no deaths in the negroid Africans.

scholarly journals Basal Cell Carcinoma of the Head and Neck Region: An Analysis of 171 Cases

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Omer Sefvan Janjua ◽  
Sana Mehmood Qureshi
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Basal Cell ◽  
Neck Region ◽  
Margin Status ◽  
Anatomical Site ◽  
Female Ratio ◽  
Head And Neck Region ◽  
Malignant Skin Tumors

Objective. To analyze the pattern of presentation of basal cell carcinoma (BCC) and margin status for excised specimens in the head and neck region.Study Design. Retrospective cross-sectional.Duration of Study.January 2009 to December 2011.Methodology. The database of the pathology department was searched to identify records of all malignant skin tumors that underwent standard excision with margins. Out of these records, tumors with a diagnosis of BCC in the head and neck region were retrieved and separated. Age, gender, anatomic location, pattern of tumor, and margin status were noted.Results. A total of 171 cases of BCC from various sites of head and neck were retrieved. Male to female ratio was 1.4 : 1. The age ranged from 22 to 90 years. Seventy-six cases presented on right side, 79 on left, and 16 were in the midline. Most common anatomical site was the nose followed by the cheek. Nodular lesions were the most common (46.2%) followed by pigmented variety (18.7%). Margins were clear in 77 (45.1%) cases, involved in 86 (50.2%) cases, and close in 8 (4.7%) cases.Conclusion. Nose was the most common site followed by the cheek. Nodular and pigmented varieties were the most frequent and margins were involved in more than fifty percent of the cases.

scholarly journals Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines

2016 ◽  
Vol 130 (S2) ◽  
pp. S125-S132 ◽  
Author(s):  
C Newlands ◽  
R Currie ◽  
A Memon ◽  
S Whitaker ◽  
T Woolford
Keyword(s):  
Squamous Cell Carcinoma ◽  
High Risk ◽  
Skin Cancer ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Annual Review ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery ◽  
Delayed Reconstruction

AbstractThis is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides consensus recommendations on the management of cutaneous basal cell carcinoma and squamous cell carcinoma in the head and neck region on the basis of current evidence.Recommendations• Royal College of Pathologists minimum datasets for NMSC should be adhered to in order to improve patient care and help work-force planning in pathology departments. (G)• Tumour depth is of critical importance in identifying high-risk cutaneous squamous cell carcinoma (cSCC), and should be reported in all cases. (R)• Appropriate imaging to determine the extent of primary NMSC is indicated when peri-neural involvement or bony invasion is suspected. (R)• In the clinically N0 neck, radiological imaging is not beneficial, and a policy of watchful waiting and patient education can be adopted. (R)• Patients with high-risk NMSC should be treated by members of a skin cancer multidisciplinary team (MDT) in secondary care. (G)• Non-infiltrative basal cell carcinoma (BCC) <2 cm in size should be excised with a margin of 4–5 mm. Smaller margins (2–3 mm) may be taken in sites where reconstructive options are limited, when reconstruction should be delayed. (R)• Where there is a high risk of recurrence, delayed reconstruction or Mohs micrographic surgery should be used. (R)• Surgical excision of low-risk cSCC with a margin of 4 mm or greater is the treatment of choice. (R)• High-risk cSCC should be excised with a margin of 6 mm or greater. (R).• Mohs micrographic surgery has a role in some high-risk cSCC cases following MDT discussion. (R)• Delayed reconstruction should be used in high-risk cSCC. (G)• Intra-operative conventional frozen section in cSCC is not recommended. (G)• Radiotherapy (RT) is an effective therapy for primary BCC and cSCC. (R)• Re-excision should be carried out for incompletely excised high-risk BCC or where there is deep margin involvement. (R)• Incompletely excised high-risk cSCC should be re-excised. (R)• Further surgery should involve confirmed marginal clearance before reconstruction. (R)• P+ N0 disease: Resection should include involved parotid tissue, combined with levels I–III neck dissection, to include the external jugular node. (R)• P+ N+ disease: Resection should include level V if that level is clinically or radiologically involved. (R)• Adjuvant RT should include level V if not dissected. (R)• P0 N+ disease: Anterior neck disease should be managed with levels I–IV neck dissection to include the external jugular node. (R)• P0 N+ posterior echelon nodal disease (i.e. occipital or post-auricular) should undergo dissection of levels II–V, with sparing of level I. (R)• Consider treatment of the ipsilateral parotid if the primary site is the anterior scalp, temple or forehead. (R)• All patients should receive education in self-examination and skin cancer prevention measures. (G)• Patients who have had a single completely excised BCC or low-risk cSCC can be discharged after a single post-operative visit. (G)• Patients with an excised high-risk cSCC should be reviewed three to six monthly for two years, with further annual review depending upon clinical risk. (G)• Those with recurrent or multiple BCCs should be offered annual review. (G)

Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon ??-2a

2005 ◽  
Vol 25 (10) ◽  
pp. 661-667 ◽  
Author(s):  
Seher Bostanci ◽  
Pelin Kocyigit ◽  
Ay??eg??l Alp ◽  
Cengizhan Erdem ◽  
Erbak G??rgey
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Basal Cell ◽  
Neck Region ◽  
Head And Neck Region
Sign in / Sign up

Export Citation Format

Share Document